002246SZSE

2025 Annual Report of Independent Director (Lv Xianpeng)

✨ AI Summary

This report outlines the performance of independent director Lv Xianpeng for 2025, emphasizing adherence to legal regulations and active participation in board meetings. Key decisions included the approval of related party transactions and the appointment of senior management. The report confirms that all actions taken were in the best interest of the company and its shareholders, with no conflicts of interest reported.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

2025 Annual Report of Independent Director

As an independent director of North Chemical Industry Co., Ltd. (hereinafter referred to as "the Company"), I have diligently fulfilled my responsibilities in 2025 in accordance with the Company Law, Securities Law, Management Measures for Independent Directors of Listed Companies, Shenzhen Stock Exchange Listing Rules, and relevant regulations. I have actively engaged in understanding the Company's operations and development, attended board and shareholder meetings, participated in major decisions, and provided independent and objective opinions to safeguard the overall interests of the Company and the legitimate rights of all shareholders. Below is my performance report for 2025:

1. Basic Information of the Independent Director

Lv Xianpeng, male, born in January 1964, Chinese nationality, without permanent residency abroad, holds a Ph.D. in Accounting. Currently, I am a professor and doctoral supervisor at Southwestern University of Finance and Economics, an independent director of Sichuan Tianwei Food Group Co., Ltd., an independent director of Luzhou Laojiao Co., Ltd., and an independent director of North Chemical Industry Co., Ltd.

2. Overview of Independent Director's Annual Performance

(1) Meeting Attendance

In 2025, the Company held 9 board meetings and 4 shareholder meetings. My attendance record is as follows:

Meeting TypeTotal MeetingsIn-Person AttendanceAttendance by CommunicationProxy AttendanceAbsencesConsecutive AbsencesShareholder Meeting Attendance
Board Meeting92610No2

In 2025, I also served as the convener of the Audit Committee, a member of the Nomination Committee, the Compensation and Assessment Committee, and the Strategy Committee of the fifth board. After the board re-election, I became the convener of the Audit Committee of the sixth board and a member of the Nomination Committee. My attendance at committee meetings and special meetings for independent directors is as follows:

Meeting NameTotal MeetingsIn-Person AttendanceProxy AttendanceAbsences
Audit Committee6600
Nomination Committee2200
Compensation Committee1100
Strategy Committee3300
Special Meeting of Independent Directors4400

For all proposals reviewed at the above meetings, I diligently examined the materials provided by the Company, fully understood the relevant circumstances, and offered opinions and suggestions as an accounting professional. I independently, objectively, and prudently exercised my voting rights, safeguarding the legitimate rights of the Company and all shareholders. I supported all proposals discussed in the meetings held in 2025, with no objections or abstentions.

(2) Exercise of Special Powers as Independent Director

As an independent director, I have diligently fulfilled my responsibilities and exercised my powers in accordance with the law, providing professional opinions at board meetings and special committee meetings.

  1. There were no instances where independent directors proposed to convene a board meeting.
  2. There were no proposals from independent directors to hire or dismiss accounting firms.
  3. There were no independent directors who independently hired external audit or consulting firms.
  4. There were no proposals from independent directors to convene an extraordinary shareholder meeting.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.